|
1
|
Wolff-Holz E, Tiitso K, Vleminckx C and
Weise M: Evolution of the EU biosimilar framework: Past and future.
BioDrugs. 33:621–634. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Malaviya AN and Mehra NK: A fascinating
story of the discovery and development of biologicals for use in
clinical medicine. Indian J Med Res. 148:263–278. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Sirbu CA, Sirbu OM, Constantin C and Sandu
AM: Neuroimunotoxicity of aluminium. Farmacia. 63:8–10. 2015.
|
|
4
|
de Leiva A, Brugués E and de Leiva-Pérez
A: The discovery of insulin: Continued controversies after ninety
years. Endocrinol Nutr. 58:449–456. 2011.(In Spanish). PubMed/NCBI View Article : Google Scholar
|
|
5
|
Carrel A: Cultivation of adult tissues and
organs outside of the human body. JAMA. 55:1379–1381. 1910.
|
|
6
|
Rodriguez-Hernandez CO, Torres-Garcia SE,
Olvera-Sandoval C, Ramirez-Castillo FY, Muro AL, Avelar-Gonzalez FJ
and Guerrero-Barrera AL: Cell culture: History, development and
prospects. Int J Curr Res Acad Rev. 2:188–200. 2014.
|
|
7
|
von Behring E and Kitasato S: The
mechanism of immunity in animals to diphtheria and tetanus.
Deutscbe Mediziniscbe W'ochenschift. 16:1145–1148. 1890.
|
|
8
|
Kaufmann SH: Remembering Emil von Behring:
From tetanus treatment to antibody cooperation with phagocytes.
MBio. 8:e00117–e17. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Llewelyn MB, Hawkins RE and Russell SJ:
Discovery of antibodies. BMJ. 305:1269–1272. 1992.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Buss NA, Henderson SJ, McFarlane M,
Shenton JM and de Haan L: Monoclonal antibody therapeutics: History
and future. Curr Opin Pharmacol. 12:615–622. 2012.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Hawkins RE, Llewelyn MB and Russell SJ:
Adapting antibodies for clinical use. BMJ. 305:1348–1352.
1992.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Köhler G and Milstein C: Continuous
cultures of fused cells secreting antibody of predefined
specificity. Nature. 256:495–497. 1975.PubMed/NCBI View
Article : Google Scholar
|
|
13
|
Liu JK: The history of monoclonal antibody
development - Progress, remaining challenges and future
innovations. Ann Med Surg (Lond). 3:113–116. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Nadler LM, Stashenko P, Hardy R, Kaplan
WD, Button LN, Kufe DW, Antman KH and Schlossman SF: Serotherapy of
a patient with a monoclonal antibody directed against a human
lymphoma-associated antigen. Cancer Res. 40:3147–3154.
1980.PubMed/NCBI
|
|
15
|
Nadler LM, Stashenko P, Hardy R and
Schlossman SF: A monoclonal antibody defining a lymphoma-associated
antigen in man. J Immunol. 125:570–577. 1980.PubMed/NCBI
|
|
16
|
Nadler LM, Stashenko P, Hardy R, Tomaselli
KJ, Yunis EJ, Schlossman SF and Pesando JM: Monoclonal antibody
identifies a new Ia-like (p29,34) polymorphic system linked to the
HLA-D/DR region. Nature. 290:591–593. 1981.PubMed/NCBI View
Article : Google Scholar
|
|
17
|
Cai HH: Therapeutic monoclonal antibodies
approved by FDA in 2017. MOJ Immunol. 6:82–84. 2018.
|
|
18
|
Tjandra JJ, Ramadi L and McKenzie IF:
Development of human anti-murine antibody (HAMA) response in
patients. Immunol Cell Biol. 68:367–376. 1990.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Jones PT, Dear PH, Foote J, Neuberger MS
and Winter G: Replacing the complementarity-determining regions in
a human antibody with those from a mouse. Nature. 321:522–525.
1986.PubMed/NCBI View
Article : Google Scholar
|
|
20
|
Morrison SL, Johnson MJ, Herzenberg LA and
Oi VT: Chimeric human antibody molecules: Mouse antigen-binding
domains with human constant region domains. Proc Natl Acad Sci USA.
81:6851–6855. 1984.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Boulianne GL, Hozumi N and Shulman MJ:
Production of functional chimaeric mouse/human antibody. Nature.
312:643–646. 1984.PubMed/NCBI View
Article : Google Scholar
|
|
22
|
Chames P, Van Regenmortel M, Weiss E and
Baty D: Therapeutic antibodies: Successes, limitations and hopes
for the future. Br J Pharmacol. 157:220–233. 2009.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Foltz IN, Gunasekaran K and King CT:
Discovery and bio-optimization of human antibody therapeutics using
the XenoMouse® transgenic mouse platform. Immunol Rev.
270:51–64. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Scott CT: Mice with a human touch. Nat
Biotechnol. 25:1075–1077. 2007.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Mayrhofer P and Kunert R: Nomenclature of
humanized mAbs: Early concepts, current challenges and future
perspectives. Hum Antibodies. 27:37–51. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Lai Y, Wang R, Chen X, Tang D, Hu Y, Cai
J, Zhang Q and Hu H: Emerging trends and new developments in
monoclonal antibodies: A scientometric analysis (1980-2016). Hum
Vaccin Immunother. 13:1–10. 2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Marcu DR, Ionita-Radu F, Iorga LD, Manea
M, Socea B, Scarneciu I, Isvoranu G, Costache R, Diaconu CC and
Bratu OG: Vascular involvement in primary retroperitoneal tumors.
Rev Chim. 70:445–448. 2019.
|
|
28
|
Marcu RD, Diaconu CC, Constantin T, Socea
B, Ionita-Radu F, Mischianu DLD and Bratu OG: Minimally invasive
biopsy in retroperitoneal tumors (Review). Exp Ther Med.
18:5016–5020. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Foster GR, Coppola C, Derbala M, Ferenci
P, Orlandini A, Reddy KR, Tallarico L, Shiffman ML, Ahlers S,
Bakalos G, et al: GUARD-C Study Group: Impact of safety-related
dose reductions or discontinuations on sustained virologic response
in HCV-infected patients: Results from the GUARD-C cohort. PLoS
One. 11(e0151703)2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Crisu GC, Ionita-Radu F, Costache RS,
Balaban VD, Nuta P, Stoica V, Vutcan LO, Stefan I, Naftanaila FM
and Jinga M: Efficacy and safety of
ombitasvir/paritaprevir/ritonavir + dasabuvir and ribavirin in
patients with compensated HCV cirrhosis. Rom J Mil Med. 122:22–26.
2019.
|
|
31
|
Sirbu CA, Budisteanu M and Falup-Pecurariu
C: Monoclonal antibodies - A revolutionary therapy in multiple
sclerosis. Neurol Neurochir Pol. 54:21–27. 2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Mantegazza R and Antozzi C: When
myasthenia gravis is deemed refractory: Clinical signposts and
treatment strategies. Ther Adv Neurol Disord.
11(1756285617749134)2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Edvinsson L: CGRP antibodies as
prophylaxis in migraine. Cell. 175(1719)2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Institute for Safe Medication Practices
(ISMP): News Item ISMP reports on safety of new migraine
preventives. Reactions Weekly 1768: 2, 2019.
|
|
35
|
American Headache Society: The American
Headache Society position statement on integrating new migraine
treatments into clinical practice. Headache 59: 1-18, 2019.
|
|
36
|
Carmine Belin A, Ran C and Edvinsson L:
Calcitonin gene- related peptide (CGRP) and cluster headache. Brain
Sci. 10(30)2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Kuroda H and Fujihara K: Current status
and prospects of complement-targeting therapy for neuromyelitis
optica. Brain Nerve. 71:573–580. 2019.(In Japanese). PubMed/NCBI View Article : Google Scholar
|
|
38
|
Oyama M, Okada K, Masuda M, Shimizu Y,
Yokoyama K, Uzawa A, Kawaguchi N, Ikeguchi R, Hoshino Y, Hatano T,
et al: Suitable indications of eculizumab for patients with
refractory generalized myasthenia gravis. Ther Adv Neurol Disord.
13(1756286420904207)2020.PubMed/NCBI View Article : Google Scholar
|
